Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

468 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Human T helper cell epitopes overlap B cell and putative cytotoxic T cell epitopes in the E2 protein of human papillomavirus type 16.
Lehtinen M, Hibma MH, Stellato G, Kuoppala T, Paavonen J. Lehtinen M, et al. Biochem Biophys Res Commun. 1995 Apr 17;209(2):541-6. doi: 10.1006/bbrc.1995.1535. Biochem Biophys Res Commun. 1995. PMID: 7733923
Introducing human papillomavirus vaccines - questions remain.
Paavonen J, Lehtinen M. Paavonen J, et al. Ann Med. 2008;40(3):162-6. doi: 10.1080/07853890701802404. Ann Med. 2008. PMID: 18382882 Review.
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G; HPV PATRICIA study group. Paavonen J, et al. Lancet. 2007 Jun 30;369(9580):2161-2170. doi: 10.1016/S0140-6736(07)60946-5. Lancet. 2007. PMID: 17602732 Clinical Trial.
Prevalence and risk factors of squamous intraepithelial lesions of the cervix among HIV-infected women - a long-term follow-up study in a low-prevalence population.
Lehtovirta P, Finne P, Nieminen P, Skogberg K, Savonius H, Paavonen J, Heikinheimo O. Lehtovirta P, et al. Int J STD AIDS. 2006 Dec;17(12):831-4. doi: 10.1258/095646206779307649. Int J STD AIDS. 2006. PMID: 17212861
Vaccination against human papillomaviruses shows great promise.
Lehtinen M, Paavonen J. Lehtinen M, et al. Lancet. 2004 Nov 13-19;364(9447):1731-2. doi: 10.1016/S0140-6736(04)17410-2. Lancet. 2004. PMID: 15541429 No abstract available.
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.
Castellsagué X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmerón J, Apter D, Kitchener H, Teixeira JC, Skinner SR, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Peters K, Tjalma WA, Safaeian M, Raillard A, Descamps D, Struyf F, Dubin G, Rosillon D, Baril L. Castellsagué X, et al. J Infect Dis. 2014 Aug 15;210(4):517-34. doi: 10.1093/infdis/jiu139. Epub 2014 Mar 8. J Infect Dis. 2014. PMID: 24610876 Free PMC article. Clinical Trial.
Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.
Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, Kuortti M, Natunen K, Palmroth J, Petäjä T, Pukkala E, Siitari-Mattila M, Struyf F, Nieminen P, Paavonen J, Dubin G, Dillner J. Lehtinen M, et al. BMJ Open. 2017 Aug 18;7(8):e015867. doi: 10.1136/bmjopen-2017-015867. BMJ Open. 2017. PMID: 28821519 Free PMC article. Clinical Trial.
468 results
Jump to page
Feedback